The molecular pathology of cognitive decline: Focus on metals

In the past two decades there have been significant advances made in understanding the cellular and molecular alterations that occur with brain ageing, as well as with our understanding of age-related brain diseases. Ageing is associated with a mid-life decline in many cognitive domains (eg. Attenti...

Full description

Saved in:
Bibliographic Details
Main Author: Roger Chung (auth)
Other Authors: Paul A. Adlard (auth)
Format: Book Chapter
Published: Frontiers Media SA 2016
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02989naaaa2200361uu 4500
001 doab_20_500_12854_53855
005 20210211
020 |a 978-2-88919-720-0 
020 |a 9782889197200 
024 7 |a 10.3389/978-2-88919-720-0  |c doi 
041 0 |a English 
042 |a dc 
100 1 |a Roger Chung  |4 auth 
700 1 |a Paul A. Adlard  |4 auth 
245 1 0 |a The molecular pathology of cognitive decline: Focus on metals 
260 |b Frontiers Media SA  |c 2016 
300 |a 1 electronic resource (175 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a In the past two decades there have been significant advances made in understanding the cellular and molecular alterations that occur with brain ageing, as well as with our understanding of age-related brain diseases. Ageing is associated with a mid-life decline in many cognitive domains (eg. Attention, working memory, episodic memory) that progresses with advancing age and which may be potentiated by a variety of diseases. However, despite the breadth of attempts to explain it, the underlying basis for age-related memory impairment remains poorly understood. Both normal and "pathological" ageing (as in age-related neurodegenerative disorders such as Alzheimer's disease) may be associated with overlapping and increased levels of "abnormal" pathology, and this may be a potential mediator of cognitive decline in both populations. An emerging hypothesis in this field is that metal ion dys/homeostasis may represent a primary unifying mechanism to explain age- and disease-associated memory impairment - either indirectly via an effect on disease pathogenesis, or by a direct effect on signaling pathways relevant to learning and memory. There remains a concerted worldwide effort to deliver an effective therapeutic treatment for cognitive decline associated with ageing and/or disease, which is currently an unmet need. There have been numerous clinical trials conducted specifically testing drugs to prevent cognitive decline and progression to dementia, but to date the results have been less than impressive, highlighting the urgent need for a greater understanding of the neurobiological basis of memory impairment in ageing and disease which can then drive the search for effective therapeutics. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
653 |a Down Syndrome 
653 |a Amyotrophic Lateral Sclerosis 
653 |a Parkinson's disease 
653 |a aluminium 
653 |a Iron 
653 |a TBI 
653 |a Cognition 
653 |a Copper 
653 |a Alzheimer's disease 
653 |a Zinc 
856 4 0 |a www.oapen.org  |u http://journal.frontiersin.org/researchtopic/1341/the-molecular-pathology-of-cognitive-decline-focus-on-metals  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/53855  |7 0  |z DOAB: description of the publication